Is Diamondback Energy a Good Stock to Buy?
Diamondback Energy (FANG) is a lesser-known diamond in the rough…
Sell
24
TRDA Quote, Financials, Valuation and Earnings
Last price:
$9.87
Seasonality move
:
1.7%
Day range:
$10.08 - $10.87
52-week range:
$10.08 - $21.79
Dividend yield:
0%
P/E ratio:
5.33x
P/S ratio:
1.86x
P/B ratio:
0.89x
Volume:
66.9K
Avg. volume:
118.3K
1-year change:
-23.95%
Market cap:
$382.5M
Revenue:
$210.8M
EPS (TTM):
$1.91
Earnings Data
Next earnings date for TRDA
May 07
2025
Most recent earnings per share
$0.03
Beat by $0.69
(Feb 27/2025)
Consensus Estimate
-$0.66
(Feb 27/2025)
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
TRDA Quarterly Earnings History
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 05/07/2025 | Q1 | $11.6M | -- | -- | -$0.69 | -- |
| 02/27/2025 | Q4 | $12.9M | $37.4M | $0.03 | -$0.66 | $0.69 |
| 11/05/2024 | Q3 | $11.9M | $19.6M | -$0.35 | -$0.63 | $0.28 |
| 08/13/2024 | Q2 | $36.4M | $94.7M | $1.55 | $0.33 | $1.22 |
| 05/07/2024 | Q1 | $15.2M | $59.1M | $0.68 | -$0.47 | $1.15 |
| 03/13/2024 | Q4 | $23.7M | $41.8M | -$0.29 | -$0.14 | -$0.15 |
| 11/07/2023 | Q3 | $9.6M | $43.7M | $1.02 | -$0.63 | $1.65 |
| 08/08/2023 | Q2 | $9.8M | $18.2M | -$0.78 | -$0.60 | -$0.18 |
| 05/10/2023 | Q1 | $79.3M | $25.3M | -$0.21 | -$0.84 | $0.63 |
| 03/06/2023 | Q4 | -- | -- | -$0.79 | -$0.83 | $0.04 |
| 11/07/2022 | Q3 | -- | -- | -$0.80 | -- | -- |
| 08/11/2022 | Q2 | -- | -- | -$0.74 | -- | -- |
| 05/12/2022 | Q1 | -- | -- | -$0.69 | -- | -- |
| 03/15/2022 | Q4 | -- | -- | -$0.89 | -- | -- |
| 12/09/2021 | Q3 | -- | -- | -$0.51 | -- | -- |
| 06/30/2021 | Q2 | -- | -- | -$0.48 | -- | -- |
| 03/31/2021 | Q1 | -- | -- | -$0.41 | -- | -- |
| 12/31/2020 | Q4 | -- | -- | -$0.42 | -- | -- |
| 09/30/2020 | Q3 | -- | -- | -$0.34 | -- | -- |
Entrada Therapeutics Earnings Questions
-
How Much did Entrada Therapeutics Generate in Revenue Last Quarter?
Entrada Therapeutics reported $37.4M worth of top line sales in its most recent quarter.
-
Did Entrada Therapeutics Beat Earnings Last Quarter?
Entrada Therapeutics announced earnings per share of $0.03 which represents a beat of analyst forecast a -$0.66 per share.
-
Is Entrada Therapeutics Profitable?
Entrada Therapeutics reported -- that represents -- per share over the last quarter.
-
What is the Analyst Consensus for Entrada Therapeutics EPS Next Year?
Entrada Therapeutics's earnings are forecast to decrease from $1.68 per share to $1.07 per share next year representing a decrease of -100%.
-
When is Entrada Therapeutics's Earnings Date?
Entrada Therapeutics's next earnings date is May 7, 2025.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is Hindsight Bias In Investing?
You’ve probably heard the expression “hindsight is 20/20.” That saying…
Is Rivian a Good Stock a Buy?
Rivian Automotive (RIVN) had an initial IPO of close to…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
29
UNF alert for Mar 26
UniFirst [UNF] is up 0.24% over the past day.
Sell
30
KEQU alert for Mar 26
Kewaunee Scientific [KEQU] is down 1.45% over the past day.
Buy
82
EPAC alert for Mar 26
Enerpac Tool Group [EPAC] is down 3.19% over the past day.
